Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.006
N. Sudhakar
To determine the co-existence of bronchial asthma in patients of bronchiectasis, and to compare the clinico-radiological profile between patients having only bronchiectasis and both bronchiectasis and bronchial asthma.: 67 patients who presented as Bronchiectasis (Clinical and radiological) to Respiratory Medicine Department at VIMS & RC, Bangalore from January 2020 to June 2021, were subjected to baseline investigations and spirometry/PEFR after informed consent. Statistical analysis was performed using SPSS 22 version software.The clinical and radiological profile were compared between the group having only bronchiectasis and those with bronchiectasis and asthma.Out of the 67 study patients, 55(82.08%) had only bronchiectasis and 12(17.91%) had bronchiectasis with bronchial asthma. In the bronchiectasis only group, majority of the patients were male 40(72.72%) and in the in bronchiectasis with bronchial asthma group majority of the patients were female 7(58.33%) which was statistically significant (P value <0.05). Patients with bronchiectasis and coexisting asthma had statistically significant increased symptoms of breathlessness, wheeze, running nose, sneezing, itching (P value <0.05). Similarly exposure to dust, fumes, pets was found to be more common in bronchiectasis with bronchial asthma group (P value >0.05). The mean age for onset of symptoms was found to be lower in the bronchiectasis with bronchial asthma group. Patients in the bronchiectasis with bronchial asthma group had a lower mean FEV1 value. Hyperinflation on chest radiograph was found to be 10.90% in bronchiectasis group, and 8.33 % in bronchiectasis with bronchial asthma group. Bilateral bronchiectasis on CT thorax was common in both groups. 17.91% of bronchiectasis patients had coexisting bronchial asthma. Hence, a proper diagnosis can reduce the burden of patients suffering from more frequent exacerbations, with better optimized treatment options.
{"title":"The coexistence of bronchial asthma in patients with bronchiectasis: A cross sectional study","authors":"N. Sudhakar","doi":"10.18231/j.ijirm.2022.006","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.006","url":null,"abstract":"To determine the co-existence of bronchial asthma in patients of bronchiectasis, and to compare the clinico-radiological profile between patients having only bronchiectasis and both bronchiectasis and bronchial asthma.: 67 patients who presented as Bronchiectasis (Clinical and radiological) to Respiratory Medicine Department at VIMS & RC, Bangalore from January 2020 to June 2021, were subjected to baseline investigations and spirometry/PEFR after informed consent. Statistical analysis was performed using SPSS 22 version software.The clinical and radiological profile were compared between the group having only bronchiectasis and those with bronchiectasis and asthma.Out of the 67 study patients, 55(82.08%) had only bronchiectasis and 12(17.91%) had bronchiectasis with bronchial asthma. In the bronchiectasis only group, majority of the patients were male 40(72.72%) and in the in bronchiectasis with bronchial asthma group majority of the patients were female 7(58.33%) which was statistically significant (P value <0.05). Patients with bronchiectasis and coexisting asthma had statistically significant increased symptoms of breathlessness, wheeze, running nose, sneezing, itching (P value <0.05). Similarly exposure to dust, fumes, pets was found to be more common in bronchiectasis with bronchial asthma group (P value >0.05). The mean age for onset of symptoms was found to be lower in the bronchiectasis with bronchial asthma group. Patients in the bronchiectasis with bronchial asthma group had a lower mean FEV1 value. Hyperinflation on chest radiograph was found to be 10.90% in bronchiectasis group, and 8.33 % in bronchiectasis with bronchial asthma group. Bilateral bronchiectasis on CT thorax was common in both groups. 17.91% of bronchiectasis patients had coexisting bronchial asthma. Hence, a proper diagnosis can reduce the burden of patients suffering from more frequent exacerbations, with better optimized treatment options.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"111 3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89398314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.005
R. R., B. Thomas, A. Rafad, Jerin James, Mekha Monsi Chenthiyethu, Ruben Thomas Lal
Tulobuterol Transdermal Drug Delivery (TTD) may be beneficial in COPD management. We aimed to study the effect of adding TTD to Triple Inhalation therapy (TI). Participants on TTD and TI (TTD-TI cohort) and, TI only (TI cohort) were identified at the out-patient pharmacy counter. There was no loss to follow-up from 35 participants each enrolled in the cohorts. They were assessed with Modified British Medical Research Council questionnaire (modified Medical Research Council), COPD Control Questionnaire (CCQ) and COPD Assessment Test (CAT). The latter two were repeated at the end of six months. The change in score were compared with Mann-Whitney-U test. Mean age of participants in years was 63.4 and 65.7; 31% and 20% were females and rest were males in TTD-TI and TI cohorts respectively. All of them had modified Medical Research Council grade 2 or above. CCQ and CAT scores were comparable at baseline. Change in both CCQ and CAT scores were statistically significant between the cohorts (p<0.001). Median (minimum, maximum) change in CCQ score were -0.6(-2.8, 0) in TTD-TI cohort and 0.3(-2 to 1.2) in TI cohort. Median (minimum, maximum) change in CAT score were -4(-16, -2) in TTD-TI cohort and 2(-7 to 7) in TI cohort. All of the participants in TTD-TI cohort and, 5(14.3%) and 7(20%) participants improved in TI cohort by CCQ and CAT score respectively. There would be a subjective improvement with addition of tulobuterol transdermal patch on to triple inhalation therapy for older persons with COPD.
妥洛勃特罗经皮给药(TTD)可能有利于COPD的治疗。我们的目的是研究在三联吸入治疗(TI)中加入TTD的效果。在门诊药房柜台确定TTD和TI的参与者(TTD-TI队列)和仅TI (TI队列)。对每组35名参与者的随访没有损失。采用修改后的英国医学研究委员会问卷(Modified Medical Research Council)、COPD控制问卷(CCQ)和COPD评估测试(CAT)对患者进行评估。后两项测试在6个月后再次进行。用Mann-Whitney-U检验比较评分变化。参与者的平均年龄为63.4岁和65.7岁;在TTD-TI和TI队列中，女性分别占31%和20%，其余为男性。均具有医学研究理事会二级或以上职级。CCQ和CAT评分在基线时具有可比性。CCQ和CAT评分在队列间的变化均有统计学意义(p<0.001)。TTD-TI组CCQ评分的中位(最小、最大)变化为-0.6(-2.8,0)，TI组为0.3(-2至1.2)。在TTD-TI组中，CAT评分的中位(最小、最大)变化为-4(-16，-2)，在TI组中为2(-7至7)。TTD-TI组全部受试者，TI组CCQ和CAT评分分别有5例(14.3%)和7例(20%)受试者改善。对于老年COPD患者，在三联吸入治疗的基础上加用妥洛特罗透皮贴片会有主观改善。
{"title":"A study on the safety profile and clinical outcomes in patients using tulobuterol transdermal patch as an add on therapy in stable chronic obstructive pulmonary disease","authors":"R. R., B. Thomas, A. Rafad, Jerin James, Mekha Monsi Chenthiyethu, Ruben Thomas Lal","doi":"10.18231/j.ijirm.2022.005","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.005","url":null,"abstract":"Tulobuterol Transdermal Drug Delivery (TTD) may be beneficial in COPD management. We aimed to study the effect of adding TTD to Triple Inhalation therapy (TI). Participants on TTD and TI (TTD-TI cohort) and, TI only (TI cohort) were identified at the out-patient pharmacy counter. There was no loss to follow-up from 35 participants each enrolled in the cohorts. They were assessed with Modified British Medical Research Council questionnaire (modified Medical Research Council), COPD Control Questionnaire (CCQ) and COPD Assessment Test (CAT). The latter two were repeated at the end of six months. The change in score were compared with Mann-Whitney-U test. Mean age of participants in years was 63.4 and 65.7; 31% and 20% were females and rest were males in TTD-TI and TI cohorts respectively. All of them had modified Medical Research Council grade 2 or above. CCQ and CAT scores were comparable at baseline. Change in both CCQ and CAT scores were statistically significant between the cohorts (p<0.001). Median (minimum, maximum) change in CCQ score were -0.6(-2.8, 0) in TTD-TI cohort and 0.3(-2 to 1.2) in TI cohort. Median (minimum, maximum) change in CAT score were -4(-16, -2) in TTD-TI cohort and 2(-7 to 7) in TI cohort. All of the participants in TTD-TI cohort and, 5(14.3%) and 7(20%) participants improved in TI cohort by CCQ and CAT score respectively. There would be a subjective improvement with addition of tulobuterol transdermal patch on to triple inhalation therapy for older persons with COPD.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"2013 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86482203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.002
S. Yadav
{"title":"Stealth omicron-A new substrain in an ongoing pandemic of COVID-19","authors":"S. Yadav","doi":"10.18231/j.ijirm.2022.002","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.002","url":null,"abstract":"","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81014683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.003
A. Trailokya, Soumen Roy
The immune system is a fundamental part of human protection against infection and disease.The immune system can occasionally lead to unfavourable reactions in the host which are known as hypersensitivity reactions. The exaggerated immune reactivity (hypersensitivity) to certain environmental substances (allergens) like airborne pollens, dust, mites, pet dander, and reactions to certain foods that normally have little effect on most people is known as allergy. The incidence of allergic disease like allergic rhinitis (AR), food borne allergy, asthma and anaphylactic reactions are prevalent in 25% of populations predominately in adolescents and adults in industrialised countries. Bilastine is a novel second-generation non-sedative, highly selective histamine H1 receptor antagonist that suppresses some allergic inflammatory processes that inhibits the release of histamine from mast cells and is approved in the treatment allergic rhinitis, urticaria and pruritus associated with skin diseases. This review covers the safety, efficacy and pharmacological aspects of Bilastine as an important product for treatment of allergic rhinitis.
{"title":"Bilastine - Novel anti histamine drug for allergic rhinitis","authors":"A. Trailokya, Soumen Roy","doi":"10.18231/j.ijirm.2022.003","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.003","url":null,"abstract":"The immune system is a fundamental part of human protection against infection and disease.The immune system can occasionally lead to unfavourable reactions in the host which are known as hypersensitivity reactions. The exaggerated immune reactivity (hypersensitivity) to certain environmental substances (allergens) like airborne pollens, dust, mites, pet dander, and reactions to certain foods that normally have little effect on most people is known as allergy. The incidence of allergic disease like allergic rhinitis (AR), food borne allergy, asthma and anaphylactic reactions are prevalent in 25% of populations predominately in adolescents and adults in industrialised countries. Bilastine is a novel second-generation non-sedative, highly selective histamine H1 receptor antagonist that suppresses some allergic inflammatory processes that inhibits the release of histamine from mast cells and is approved in the treatment allergic rhinitis, urticaria and pruritus associated with skin diseases. This review covers the safety, efficacy and pharmacological aspects of Bilastine as an important product for treatment of allergic rhinitis.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78258329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.001
Gyanshankar P. Mishra
{"title":"Therapeutic drug monitoring: The future of tuberculosis management","authors":"Gyanshankar P. Mishra","doi":"10.18231/j.ijirm.2022.001","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.001","url":null,"abstract":"","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88439925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.010
Deepak Siddavaram
Critically ill patients often have a dysregulated immune response to the underlying insult leading to varied clinical features and end-organ dysfunction. One of the dysregulated immune responses termed ‘cytokine storm (CS)’ secondary to SARS-COV-2 during the recent COVID-19 pandemic was responsible for unacceptably high morbidity and mortality across the world. Cytokine storm is not unique to just COVID-19 but can also occur due to certain other viruses like H1N1 influenza. This phenomenon accelerated not only our understanding of the underlying pathophysiology and the role of the immune system in critically ill patients but also strengthened the concept of the possible need for an immunomodulator incorporated with standard therapy for treating Acute Respiratory Distress Syndrome(ARDS). Itolizumab, a reformulated anti-CD-6 humanized monoclonal antibody, downregulates the synthesis of proinflammatory cytokines leading to reduced interferon-γ (IFNγ), interleukin (IL-6), and tumour necrosis factor-α (TNFα) levels, along with reduced T-cell infiltration at the inflammatory site. Its usage in the management of CS in non-COVID 19 ARDS seems to be an appealing therapeutic approach given its mechanism of action. The current cases highlight an underlying possible hyperimmune response secondary to H1N1 in two patients who were successfully managed using Itolizumab along with standard treatment of ARDS.
{"title":"Successful management of cytokine storm induced acute respiratory distress syndrome secondary to H1N1 influenza with itolizumab: A case series","authors":"Deepak Siddavaram","doi":"10.18231/j.ijirm.2022.010","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.010","url":null,"abstract":"Critically ill patients often have a dysregulated immune response to the underlying insult leading to varied clinical features and end-organ dysfunction. One of the dysregulated immune responses termed ‘cytokine storm (CS)’ secondary to SARS-COV-2 during the recent COVID-19 pandemic was responsible for unacceptably high morbidity and mortality across the world. Cytokine storm is not unique to just COVID-19 but can also occur due to certain other viruses like H1N1 influenza. This phenomenon accelerated not only our understanding of the underlying pathophysiology and the role of the immune system in critically ill patients but also strengthened the concept of the possible need for an immunomodulator incorporated with standard therapy for treating Acute Respiratory Distress Syndrome(ARDS). Itolizumab, a reformulated anti-CD-6 humanized monoclonal antibody, downregulates the synthesis of proinflammatory cytokines leading to reduced interferon-γ (IFNγ), interleukin (IL-6), and tumour necrosis factor-α (TNFα) levels, along with reduced T-cell infiltration at the inflammatory site. Its usage in the management of CS in non-COVID 19 ARDS seems to be an appealing therapeutic approach given its mechanism of action. The current cases highlight an underlying possible hyperimmune response secondary to H1N1 in two patients who were successfully managed using Itolizumab along with standard treatment of ARDS.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73739561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.004
K. Thakkar, C. Verma, Aditi Parekh
The ‘Post COVID Functional Status Scale’ (PCFS) is an ordinal scale concentrating on the functional limitations to view the variety of post-COVID 19 outcomes and to measure the consequence of the infection other than death The adapted version of the PCFS Scale will be useful in tracking the post COVID functional status in the individuals who can comprehend the scale better in the Gujarati language. This study was carried out in a post-COVID-19 patient population at a government tertiary care hospital. The study was carried out according to the guidelines given by the American Association of Orthopaedic Surgeons. The methodology consisted of 3 Phases. Forward and backward translation, expert committee review, and usability testing on the participants who were asked to fill out the Gujarati version of the PCFS scale twice in Phase 1, 2, and 3 respectively.30 participants, both males, and females participated in the study. Cronbach’s α was used to calculate the internal consistency of the scale. The ICC was 0.99, which interprets as a very high correlation and stability of the scale.The Cronbach’s alpha was calculated for a population of 30 participants. On test 1 the value for Cronbach’s Alpha (ɑ1) was 0.821 and on the second test, the value was (ɑ2) 0.866. A linguistically and practically identical Gujarati PCFS Scale was formulated after a careful and systematic process, which offers a viable and trustworthy method for assessing the functionality of post-COVID-19 patients.
{"title":"Translation and psychometric properties of the Gujarati version post-COVID functional status scale","authors":"K. Thakkar, C. Verma, Aditi Parekh","doi":"10.18231/j.ijirm.2022.004","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.004","url":null,"abstract":"The ‘Post COVID Functional Status Scale’ (PCFS) is an ordinal scale concentrating on the functional limitations to view the variety of post-COVID 19 outcomes and to measure the consequence of the infection other than death The adapted version of the PCFS Scale will be useful in tracking the post COVID functional status in the individuals who can comprehend the scale better in the Gujarati language. This study was carried out in a post-COVID-19 patient population at a government tertiary care hospital. The study was carried out according to the guidelines given by the American Association of Orthopaedic Surgeons. The methodology consisted of 3 Phases. Forward and backward translation, expert committee review, and usability testing on the participants who were asked to fill out the Gujarati version of the PCFS scale twice in Phase 1, 2, and 3 respectively.30 participants, both males, and females participated in the study. Cronbach’s α was used to calculate the internal consistency of the scale. The ICC was 0.99, which interprets as a very high correlation and stability of the scale.The Cronbach’s alpha was calculated for a population of 30 participants. On test 1 the value for Cronbach’s Alpha (ɑ1) was 0.821 and on the second test, the value was (ɑ2) 0.866. A linguistically and practically identical Gujarati PCFS Scale was formulated after a careful and systematic process, which offers a viable and trustworthy method for assessing the functionality of post-COVID-19 patients. ","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90981232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.008
Subhajit Sen, Suresh Ramasubban, Chadrashish Chakravarty, Lawni Goswami, Debasis Rout, A. Mohapatra
Recent reports have described a secondary Multi system Inflammatory Syndrome in adult (MIS-A)and its temporal association with COVID-19 infection. Here, we report the case of a 25-year-old male who presented with shock and multi organ failure. Three-week prior to present admission he developed an Influenza like illness, secondary to SARS-CoV2 infection as detected by a reverse-transcription polymerase chain reaction (RT-PCR). Three weeks later, patient had recurrence of fever associated with throat pain, neck swelling, and a rash followed by shock and multiorgan failure. Laboratory work revealed elevated inflammatory markers. His throat swab for SARS-CoV-2 by RT-PCR was negative and SARS-CoV-2 IgG antibody was reactive.In view of presentation like multi-inflammatory syndrome in children (MIS-C) a probable diagnosis of MIS-A was made. He was successfully treated with intravenous Immunoglobulin and pulse dose Methylprednisolone. This case highlights the need to remain vigilant for multisystem inflammatory syndromes in the COVID-19 affected patients.[
{"title":"A young adult with multisystem inflammatory syndrome (MIS-A) following COVID-19 infection: A case report","authors":"Subhajit Sen, Suresh Ramasubban, Chadrashish Chakravarty, Lawni Goswami, Debasis Rout, A. Mohapatra","doi":"10.18231/j.ijirm.2022.008","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.008","url":null,"abstract":"Recent reports have described a secondary Multi system Inflammatory Syndrome in adult (MIS-A)and its temporal association with COVID-19 infection. Here, we report the case of a 25-year-old male who presented with shock and multi organ failure. Three-week prior to present admission he developed an Influenza like illness, secondary to SARS-CoV2 infection as detected by a reverse-transcription polymerase chain reaction (RT-PCR). Three weeks later, patient had recurrence of fever associated with throat pain, neck swelling, and a rash followed by shock and multiorgan failure. Laboratory work revealed elevated inflammatory markers. His throat swab for SARS-CoV-2 by RT-PCR was negative and SARS-CoV-2 IgG antibody was reactive.In view of presentation like multi-inflammatory syndrome in children (MIS-C) a probable diagnosis of MIS-A was made. He was successfully treated with intravenous Immunoglobulin and pulse dose Methylprednisolone. This case highlights the need to remain vigilant for multisystem inflammatory syndromes in the COVID-19 affected patients.[","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"78 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83234902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-15DOI: 10.18231/j.ijirm.2022.009
P. Upadhya, S. C., A. Moorthy, B. N, M. R., J. B
Paraquat is a rapid-acting herbicide widely used in many parts of the world. Although it is considered safe when exposed to the body surface, ingestion of this substance is highly fatal. Organ damage is caused by the production of free radicals and the depletion of nicotinamide adenine dinucleotide phosphate (NADPH). Multiple organs are involved in the damage, particularly organs requiring high blood flow like lungs, heart, kidneys, and liver. There is no proven effective antidote for the poisoning, and it is nearly 100% fatal. Here, we report an 18 years old young male presenting with pneumo-mediastinum, subcutaneous emphysema with pneumo-peritoneum after paraquat ingestion, which is a rare presentation of paraquat poisoning.
{"title":"A rare cause of subcutaneous emphysema with pneumomediastinum and pneumoperitoneum in a young adult: Paraquat poisoning","authors":"P. Upadhya, S. C., A. Moorthy, B. N, M. R., J. B","doi":"10.18231/j.ijirm.2022.009","DOIUrl":"https://doi.org/10.18231/j.ijirm.2022.009","url":null,"abstract":"Paraquat is a rapid-acting herbicide widely used in many parts of the world. Although it is considered safe when exposed to the body surface, ingestion of this substance is highly fatal. Organ damage is caused by the production of free radicals and the depletion of nicotinamide adenine dinucleotide phosphate (NADPH). Multiple organs are involved in the damage, particularly organs requiring high blood flow like lungs, heart, kidneys, and liver. There is no proven effective antidote for the poisoning, and it is nearly 100% fatal. Here, we report an 18 years old young male presenting with pneumo-mediastinum, subcutaneous emphysema with pneumo-peritoneum after paraquat ingestion, which is a rare presentation of paraquat poisoning.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"114 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85390728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-15DOI: 10.18231/j.ijirm.2021.051
Ramakrishna Rachakonda, Shaik Umar Pasha, Shaik Abdul Waseem, Nagarjuna Reddy Sunkara, Seenu Ayyakannu
A twenty years old male college student came with history of hemoptysis. His chest X-ray showed diffuse infiltrative shadows and he was diagnosed as a case of a case of pulmonary tuberculosis with hemoptysis. On detailed investigations he was found to have Abernethy malformation Type-II with primitive portal vein joining extrahepatic inferior vanacava leading to cirrhosis of liver, porto-pulmonary syndrome, pulmonary arterial hypertension and hemoptysis.
{"title":"An unusual case of hemoptysis secondary to Abernethy malformation type II and hepatopulmonary syndrome, pulmonary arterial hypertension","authors":"Ramakrishna Rachakonda, Shaik Umar Pasha, Shaik Abdul Waseem, Nagarjuna Reddy Sunkara, Seenu Ayyakannu","doi":"10.18231/j.ijirm.2021.051","DOIUrl":"https://doi.org/10.18231/j.ijirm.2021.051","url":null,"abstract":"A twenty years old male college student came with history of hemoptysis. His chest X-ray showed diffuse infiltrative shadows and he was diagnosed as a case of a case of pulmonary tuberculosis with hemoptysis. On detailed investigations he was found to have Abernethy malformation Type-II with primitive portal vein joining extrahepatic inferior vanacava leading to cirrhosis of liver, porto-pulmonary syndrome, pulmonary arterial hypertension and hemoptysis.","PeriodicalId":14503,"journal":{"name":"IP Indian Journal of Immunology and Respiratory Medicine","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89834609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：